Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:NUVL NASDAQ:PRAX NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$111.06-4.1%$94.06$36.65▼$130.05$9.52B1.951.24 million shs544,110 shsNUVLNuvalent$123.96$114.23$71.13▼$123.99$9.79B1.141.93 million shsN/APRAXPraxis Precision Medicines$304.43-3.2%$310.80$37.19▼$366.52$8.77B2.74546,783 shs233,335 shsSLSSELLAS Life Sciences Group$12.48-5.4%$9.91$1.39▼$15.88$2.59B2.4211.27 million shs7.27 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-4.07%+0.60%+22.81%+26.10%+140.49%NUVLNuvalent0.00%+0.02%+0.43%+15.71%+48.63%PRAXPraxis Precision Medicines-3.17%-3.22%+7.84%-10.68%+465.33%SLSSELLAS Life Sciences Group-5.38%-1.11%+55.03%+148.11%+605.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$111.06-4.1%$94.06$36.65▼$130.05$9.52B1.951.24 million shs544,110 shsNUVLNuvalent$123.96$114.23$71.13▼$123.99$9.79B1.141.93 million shsN/APRAXPraxis Precision Medicines$304.43-3.2%$310.80$37.19▼$366.52$8.77B2.74546,783 shs233,335 shsSLSSELLAS Life Sciences Group$12.48-5.4%$9.91$1.39▼$15.88$2.59B2.4211.27 million shs7.27 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-4.07%+0.60%+22.81%+26.10%+140.49%NUVLNuvalent0.00%+0.02%+0.43%+15.71%+48.63%PRAXPraxis Precision Medicines-3.17%-3.22%+7.84%-10.68%+465.33%SLSSELLAS Life Sciences Group-5.38%-1.11%+55.03%+148.11%+605.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.86Moderate Buy$122.6410.42% UpsideNUVLNuvalent 2.15Hold$127.733.04% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$563.5085.10% UpsideSLSSELLAS Life Sciences Group 2.33Hold$10.00-19.87% DownsideCurrent Analyst Ratings BreakdownLatest SLS, KYMR, NUVL, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026KYMRKymera Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$120.00 ➝ $140.007/13/2026PRAXPraxis Precision Medicines Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/13/2026KYMRKymera Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$106.00 ➝ $115.007/13/2026PRAXPraxis Precision Medicines The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$447.007/13/2026PRAXPraxis Precision Medicines The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$447.007/6/2026SLSSELLAS Life Sciences Group Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026KYMRKymera Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.006/29/2026KYMRKymera Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$117.00 ➝ $155.006/29/2026KYMRKymera Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$116.00 ➝ $136.006/29/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$537.00 ➝ $575.006/26/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $129.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$39.21M233.00N/AN/A$19.42 per share5.72NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/APRAXPraxis Precision Medicines$8.55M992.69N/AN/A$34.85 per share8.74SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest SLS, KYMR, NUVL, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026SLSSELLAS Life Sciences Group-$0.0450N/AN/AN/AN/AN/A8/10/2026Q2 2026KYMRKymera Therapeutics-$0.7266N/AN/AN/A$31.17 millionN/A8/6/2026Q2 2026NUVLNuvalent-$1.44N/AN/AN/A$0.25 millionN/A8/3/2026Q2 2026PRAXPraxis Precision Medicines-$3.6684N/AN/AN/A$1.25 millionN/A5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A10.8110.81NUVLNuvalentN/A16.1416.14PRAXPraxis Precision MedicinesN/A15.8815.88SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/ANUVLNuvalent97.26%PRAXPraxis Precision Medicines67.84%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics15.98%NUVLNuvalent5.02%PRAXPraxis Precision Medicines3.00%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableSLS, KYMR, NUVL, and PRAX HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group (NASDAQ:SLS) & Abivax (NASDAQ:ABVX) Critical Comparison2 hours ago | americanbankingnews.comSLS stock hits July low as AML readout nears — retail bulls see 'stellar' hint in CEO's Fox appearance next weekJuly 18 at 1:13 PM | msn.comSELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On ReturnsJuly 18 at 8:12 AM | finance.yahoo.comSELLAS Life Sciences rebounds 12% as investors continue to wait for key dataJuly 18 at 8:12 AM | seekingalpha.comSELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial BuzzJuly 18 at 8:12 AM | finance.yahoo.comSellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial ResultJuly 17, 2026 | insidermonkey.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 13.1% - Still a Buy?July 17, 2026 | marketbeat.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.5% - Here's What HappenedJuly 16, 2026 | marketbeat.comSLS stock jumps overnight after new investor disclosure – retail flags ‘massive’ options bet ahead of AML dataJuly 14, 2026 | msn.comSELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught UpJuly 14, 2026 | seekingalpha.comInvestors Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)July 13, 2026 | marketbeat.comSellas Life Sciences: REGAL Trial's Delayed Events Signal Selection BiasJuly 9, 2026 | seekingalpha.comHere’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026July 9, 2026 | finance.yahoo.comSLS stock in the spotlight as CEO pushes back on Regal trial criticism – 'Let's separate the noise from the data'July 8, 2026 | msn.comMost and least shorted mid- to mega-cap healthcare stocks at the end of JuneJuly 1, 2026 | seekingalpha.comSELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial DataJuly 1, 2026 | finance.yahoo.comDoes SELLAS (SLS) Executive Severance Reset Hint at M&A Readiness or Standalone Ambition?June 30, 2026 | uk.finance.yahoo.comWhy Sellas Remains A Strong Sell After Doubling In PriceJune 30, 2026 | seekingalpha.comSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?June 30, 2026 | benzinga.comSellas Life (SLS) Climbs to Record High on Acquisition BuzzJune 30, 2026 | finance.yahoo.comSellas Life Sciences shares break out to new 52-week high: What's driving the momentum?June 29, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, KYMR, NUVL, and PRAX Company DescriptionsKymera Therapeutics NASDAQ:KYMR$111.06 -4.71 (-4.07%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$113.06 +2.00 (+1.80%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Nuvalent NASDAQ:NUVL$123.96 0.00 (0.00%) As of 07/16/2026Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$304.43 -9.98 (-3.17%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$315.76 +11.33 (+3.72%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$12.48 -0.71 (-5.38%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$12.59 +0.11 (+0.88%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Why Gold Miners Could Be the Market's Biggest Comeback Story A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
